Inflammatory bowel disease: new insights into pathogenesis and treatment
- 11 December 2002
- journal article
- review article
- Published by Wiley in Journal of Internal Medicine
- Vol. 252 (6), 475-496
- https://doi.org/10.1046/j.1365-2796.2002.01067.x
Abstract
Ardizzone S, Bianchi Porro G (‘L. Sacco’ University Hospital, Milan, Italy). Inflammatory bowel disease: new insights into pathogenesis and treatment (Review). J Intern Med 2002; 252: 475–496. Despite all the advances in our understanding of the pathophysiology of inflammatory bowel disease (IBD), we do not know the cause. Some of the most recently available data have been discussed here and yet it is now becoming increasingly accepted that immunogenetics play an important role in the predisposition, modulation, and perpetuation of IBD. The mucosal immune system is the central effector of intestinal inflammation and injury, with cytokines playing a central role in modulating inflammation. The role of intestinal milium, and enteric flora in particular, appears to be of greater significance than previously held. A review is made of the main areas of research exploring the mechanisms more intimately associated with the development of IBD, providing advances in the agents currently used, and identifying a host of new therapeutic agents potentially interacting with or interrupting specific targets in the genesis of IBD.Keywords
This publication has 101 references indexed in Scilit:
- Maintenance infliximab for Crohn's disease: the ACCENT I randomised trialThe Lancet, 2002
- Crohn's diseaseThe Lancet, 2002
- Infliximab for the Treatment of Fistulas in Patients with Crohn's DiseaseNew England Journal of Medicine, 1999
- The immunomodulation of enteric neuromuscular function: Implications for motility and inflammatory disordersGastroenterology, 1996
- Nicotine in Ulcerative ColitisClinical Immunotherapeutics, 1996
- HLA-DRB1*1502 allele, subtype of DR15, is associated with susceptibility to ulcerative colitis and its progressionDigestive Diseases and Sciences, 1995
- Transdermal Nicotine for Active Ulcerative ColitisNew England Journal of Medicine, 1994
- Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation.The Journal of Experimental Medicine, 1993
- Treatment of the mucosa with local anaesthetics in ulcerative colitisInflammation Research, 1992
- Treatment of Ulcerative Colitis With ClonidineThe Journal of Clinical Pharmacology, 1985